- Home
- EA vs TAK Comparison
EA vs TAK Comparison
Compare EA & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EA | TAK |
|---|---|---|
| Founded | 1982 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.1B | 43.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EA | TAK |
|---|---|---|
| Price | $204.13 | $16.30 |
| Analyst Decision | Buy | |
| Analyst Count | 22 | 0 |
| Target Price | ★ $185.81 | N/A |
| AVG Volume (30 Days) | 1.8M | ★ 2.5M |
| Earning Date | 02-03-2026 | 01-29-2026 |
| Dividend Yield | 0.37% | ★ 3.22% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.45 | 0.14 |
| Revenue | $7,288,000,000.00 | ★ $29,846,840,032.00 |
| Revenue This Year | $11.26 | N/A |
| Revenue Next Year | $3.67 | $0.47 |
| P/E Ratio | ★ $59.17 | $117.49 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $115.21 | $12.80 |
| 52 Week High | $204.89 | $16.42 |
Technical Indicators
Market Signals| Indicator | EA | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 58.08 | 79.63 |
| Support Level | $204.25 | $15.48 |
| Resistance Level | $204.68 | $16.42 |
| Average True Range (ATR) | 0.48 | 0.19 |
| MACD | -0.17 | 0.07 |
| Stochastic Oscillator | 59.73 | 92.84 |
Price Performance
Historical ComparisonAbout EA Electronic Arts Inc.
Electronic Arts is one of the largest global developers and publishers of video games. Its most important franchises are the Madden NFL and FC soccer games, which it releases annually. In 2024, it also relaunched its American college football game. Other major franchises include Apex Legends, Battlefield, and The Sims. Typically, about three quarters of the firm's sales are from in-game spending, with the remainder coming from initial game sales.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.